Brief: HLS Says Vascepa Is Now Reimbursed By Ontario's Provincial Drug Plan
July 25 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS ANNOUNCES THAT VASCEPA® IS NOW REIMBURSED BY ONTARIO'S
PROVINCIAL DRUG PLAN
* HLS THERAPEUTICS INC - PLA WITH ONTARIO IS EFFECTIVE JULY
21,
2022
Source text for Eikon: ID:nCNWd5HyWa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease